Key stats
About SELECTRA J. LAMARCK BIOTECH CLASS D
Home page
Inception date
Jan 24, 2011
Structure
Luxembourg SICAV
Dividend treatment
Capitalizes
Primary advisor
J Lamarck SpA
ISIN
LU1246176264
The main objective of this Sub-Fund is to profit from increasing share prices in the biotechnology sector. The focus is on mature top tier pharmaceutical biotech companies and companies with interesting pipeline of products in development in a single or numerous markets, like Nasdaq or NYSE.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks98.76%
Health Technology97.85%
Bonds, Cash & Other1.24%
Mutual fund2.17%
Cash−0.94%
Stock breakdown by region
North America76.06%
Europe23.94%
Latin America0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
SELJLB top holdings are Exelixis, Inc. and Ionis Pharmaceuticals, Inc., occupying 9.96% and 9.64% of the portfolio correspondingly.
No, SELJLB doesn't pay dividends to its holders.
SELJLB shares are issued by J Lamarck SpA under the brand Selectra Investments. The ETF was launched on Jan 24, 2011, and its management style is Active.
SELJLB expense ratio is 3.36% meaning you'd have to pay 3.36% of your investment to help manage the fund.
SELJLB follows the No Underlying Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
SELJLB invests in stocks.
SELJLB price has risen by 8.04% over the last month, and its yearly performance shows a −18.17% decrease. See more dynamics on SELJLB price chart.
NAV returns, another gauge of an ETF dynamics, showed a −13.80% decrease in three-month performance and has decreased by −16.60% in a year.
NAV returns, another gauge of an ETF dynamics, showed a −13.80% decrease in three-month performance and has decreased by −16.60% in a year.
SELJLB trades at a premium (4.46%) meaning the ETF is trading at a higher price than the calculated NAV.